Analytical Data
-
Gene name
NRN1
- Application
-
Alternative Names
NRN1；NRN；Neuritin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NPD7
-
Expression Region
28-115aa
-
AA Sequence
AGKCDAVFKG FSDCLLKLGD SMANYPQGLD DKTNIKTVCT YWEDFHSCTV TALTDCQEGA KDMWDKLRKE SKNLNIQGSL FELCGSGN
-
Molecular Weight
9.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Nuclear protein 1 (NRN1), also known as Nogo-A or Reticulon-4, is a protein primarily expressed in the central nervous system and has garnered significant interest in neuroscience and regenerative medicine due to its role in axonal growth inhibition and neuronal regeneration. In the context of nervous system injuries, such as spinal cord injuries or neurodegenerative diseases, NRN1 has been shown to contribute to the suppression of neural repair mechanisms, impeding the regrowth of axons and the restoration of functional connectivity. Recent studies have focused on the potential of NRN1 as a therapeutic target, exploring the development of NRN1 recombinant proteins that inhibit its activity, thereby promoting neuronal regeneration. These recombinant proteins are designed to block the inhibitory pathways mediated by NRN1, encouraging axonal sprouting and facilitating functional recovery after injury. Additionally, research into the structural and biochemical properties of NRN1 has provided insights into its interactions with other cellular components, enhancing our understanding of its biological functions. The ongoing investigation into NRN1 and its recombinant variants holds promise for developing innovative strategies to enhance neural repair and improve outcomes in patients with nerve damage.
